Immunogenicity and safety of bnt162b2 homologous booster vaccination in people living with hiv under effective cart

HIGHLIGHTS

• who: Laura Gianserra et al. from the (UNIVERSITY) have published the research work: Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART, in the Journal: Vaccines 2022, 10, 1243. of 12/07/2022
• what: The authors report updated data about the immunogenicity and safety of the booster dose with the same vaccine. Of the 63 subjects who completed the primary vaccination, 21 (33.3%) were not included in this study for the following reasons: two were already reactive at T0, three tested positive for SARS-CoV-2 after . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.